Literature DB >> 1984995

Zollinger-Ellison syndrome. Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion.

A Fich1, N J Talley, R G Shorter, S F Phillips.   

Abstract

Since Helicobacter pylori infects the gastric mucosa in most patients with chronic duodenal ulcer, infection with this organism has been implicated in the pathogenesis of this common disease. We postulated that if H. pylori is pathogenic in the usual type of duodenal ulcer, it should be less common when duodenal ulcer has another, specific etiology, such as Zollinger-Ellison syndrome. Gastric mucosa was compared from 18 patients with proven Zollinger-Ellison syndrome (17 of whom had had duodenal ulcer disease) and 18 controls with chronic duodenal ulcer without such a diagnosis. All subjects, who were matched for age and sex, had undergone elective gastric resections. Gastric tissues were stained by hematoxylin-eosin and Giemsa and were reviewed by an experienced pathologist who was unaware of the diagnosis. The frequency of H. pylori in patients with Zollinger-Ellison syndrome (8/18) was lower than in controls with duodenal ulcer (16/18; P less than 0.02). Moreover, chronic antral gastritis scores were higher in patients with duodenal ulcer (P less than 0.01). In Zollinger-Ellison syndrome, peak acid output was lower in patients positive (median 22 meq/30 min) compared to those negative for H. pylori (median 32 meq/30 min; P less than 0.02) but serum gastrin was correspondingly lower in patients positive for H. pylori (P less than 0.05). H. pylori infection appears to be more frequent when duodenal ulceration is not associated with another etiology, such as acid hypersecretion in Zollinger-Ellison syndrome. H. pylori infection in Zollinger-Ellison syndrome may also be associated with decreased gastric acid secretion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984995     DOI: 10.1007/bf01300079

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

2.  Parietal and chief cell populations in four cases of the Zollinger-Ellison syndrome.

Authors:  P Neuburger; M Lewin; C de Recherche; S Bonfils
Journal:  Gastroenterology       Date:  1972-12       Impact factor: 22.682

3.  Computed normal values for peak acid output based on age, sex and body weight.

Authors:  A H Blackman; D L Lambert; W R Thayer; H F Martin
Journal:  Am J Dig Dis       Date:  1970-09

Review 4.  Duodenal ulcer, Campylobacter pylori, and the "leaking roof" concept.

Authors:  C S Goodwin
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

5.  Campylobacter pylori and gastric acidity.

Authors:  S Wagner; J Freise; S Beholz; F W Schmidt
Journal:  Am J Gastroenterol       Date:  1989-02       Impact factor: 10.864

6.  Campylobacter pylori and Barrett's esophagus.

Authors:  N J Talley; A J Cameron; R G Shorter; A R Zinsmeister; S F Phillips
Journal:  Mayo Clin Proc       Date:  1988-12       Impact factor: 7.616

7.  Acid secretion and serum gastrin levels in individuals with Campylobacter pylori.

Authors:  C E Brady; T L Hadfield; J R Hyatt; S J Utts
Journal:  Gastroenterology       Date:  1988-04       Impact factor: 22.682

8.  Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the [13C]urea breath test in normal subjects and patients with peptic ulcer disease.

Authors:  D Y Graham; P D Klein; A R Opekun; T W Boutton
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

9.  Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.

Authors:  C P Dooley; H Cohen; P L Fitzgibbons; M Bauer; M D Appleman; G I Perez-Perez; M J Blaser
Journal:  N Engl J Med       Date:  1989-12-07       Impact factor: 91.245

10.  Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium.

Authors:  S L Hazell; A Lee; L Brady; W Hennessy
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

View more
  6 in total

Review 1.  Gastrin - active participant or bystander in gastric carcinogenesis?

Authors:  Susan A Watson; Anna M Grabowska; Mohamad El-Zaatari; Arjun Takhar
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

2.  A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration.

Authors:  K E McColl; A M el-Nujumi; R S Chittajallu; S W Dahill; C A Dorrian; E el-Omar; I Penman; E J Fitzsimons; J Drain; H Graham
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

3.  Helicobacter pylori infection. A reversible cause of hypergastrinemia and hyperchlorhydria which may mimic Zollinger-Ellison syndrome.

Authors:  D C Metz; H C Weber; M Orbuch; D B Strader; I A Lubensky; R T Jensen
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

4.  Helicobacter pylori in duodenal ulcer patients with idiopathic gastric acid hypersecretion.

Authors:  M J Collen; R M Strong
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

5.  Helicobacter pylori associated with a high prevalence of duodenal ulcer disease and a low prevalence of gastric cancer in a developing nation.

Authors:  P J Hu; Y Y Li; M H Zhou; M H Chen; G G Du; B J Huang; H M Mitchell; S L Hazell
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

Review 6.  Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.